Artios Pharma Ltd raises US-$153m Series C...Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline. more ➔
AXA IM Alts raises €1.9bn European Life...AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector. more ➔
Synaffix inks $246m deal with ProfoundBioSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal more ➔
Panakès expands into biotech with €150m...Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies. more ➔
BioNTech takes over cancer immunotherapy p...Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals. more ➔
Nanosyrinx raises £6.2m to validate drug...Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities. more ➔
€26m financing for ISA PharmaceuticalsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers. more ➔
Unilever licences Arzeda Inc.s enzyme te...As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon. more ➔
Novo Nordisk invests in amyloidosis pipeli...Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy. more ➔
Sanofi invests heavily in multiple myeloma... Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment. more ➔
